New hope for Tough-to-Treat cancers: experimental drug enters human trials
NCT ID NCT07374419
Summary
This study is testing an experimental drug called atamparib in adults with advanced lung cancer or other solid tumors that have spread. It aims to find the safest dose and see if the drug can shrink tumors in people who have already tried standard treatments and have a specific genetic change (KRAS mutation). The trial will first determine the best dose, then expand to see how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.